BPC-157 + TB-500 (Blend)
BPC-157 + TB-500 (Blend)
BPC-157 + TB-500 Blend
The image represents one available format. Strength and pack size are those selected above.
-25% on everything – until October 31
25% off regular prices, replacing other product sales. Only the crypto payment discount can be combined.
Overview
BPC-157 + TB-500 Blend
This vial contains a pre-formulated blend of BPC-157 and TB-500 , two synthetic peptides with distinct molecular mechanisms and signaling characteristics. BPC-157 has been investigated for interactions with VEGFR2-, FAK-, and eNOS-associated signaling pathways together with regulatory processes involving extracellular protein networks.
TB-500, a synthetic analogue of Thymosin Beta-4, interacts with G-actin through the conserved LKKTET motif, influencing actin-binding dynamics, cytoskeletal organization, and actin-associated signaling systems.
The co-formulated preparation provides a convenient research tool for investigating multiple peptide-mediated signaling pathways, actin-regulatory mechanisms, and pathway interactions within a single experimental framework.
.
- High Purity – 99% Purity Guaranteed
- Independently Lab Tested
- Research Grade Quality
- For Laboratory Research Use Only
Properties
| Chemical Formula | C62H98N16O22 / C212H350N56O78S |
|---|---|
| Synonyms | BPC-157 + Thymosin Beta-4 Blend, BPC/TB Blend |
| Molar Mass | 1,419.5 / 4,963.4 g/mol |
| CAS Number | 137525-51-0 | 77591-33-4 |
| PubChem CID | 9941957 / 16132341 |
| Available formats | 5mg+5mg 1 vial · 5mg+5mg 10 vials · 10mg+10mg 1 vial · 10mg+10mg 10 vials |
| Shelf Life | 36 months |
Research
This blend vial contains BPC-157 (C62H98N16O22) and TB-500 (C212H350N56O78S) in a single lyophilized preparation. The two peptides exhibit distinct molecular mechanisms and signaling characteristics. BPC-157 has been investigated for interactions with VEGFR2-, ERK1/2-, eNOS-, and FAK-associated signaling networks together with regulatory processes involving extracellular protein systems. TB-500, a synthetic analogue of Thymosin Beta-4, regulates actin-associated processes through G-actin binding via the conserved LKKTET motif, influencing cytoskeletal organization, actin polymerization dynamics, and associated signaling pathways. Experimental investigations have examined both compounds across a range of peptide-mediated regulatory systems and molecular signaling networks. The co-formulated blend provides a single preparation for researchers investigating comparative or concurrent peptide-signaling mechanisms while reducing reconstitution complexity in multi-peptide study designs. Each peptide retains its individual chemical identity and pharmacological profile within the blend. Independently third-party HPLC-tested; COA available per batch.Lab Results
Results refer to the tested sample. Check the batch and date in the report.
FAQ
Do BPC-157 and TB-500 interact with the same signaling pathways, or do they exhibit distinct mechanisms?
BPC-157 and TB-500 exhibit distinct molecular mechanisms and signaling characteristics. BPC-157 has been investigated for interactions with VEGFR2-, ERK1/2-, eNOS-, and FAK-associated signaling networks together with regulatory processes involving extracellular protein systems.
TB-500 interacts with G-actin through the conserved LKKTET motif, influencing actin polymerization dynamics, cytoskeletal organization, and actin-associated signaling pathways.
While both peptides participate in broad regulatory signaling networks, their primary molecular targets and mechanisms remain distinct, making the blend useful for comparative investigation of multiple peptide-mediated pathways.
Is the purity and identity of each peptide maintained within the blend?
Yes. BPC-157 and TB-500 remain chemically distinct components within the lyophilized preparation and do not form covalent conjugates under standard manufacturing and storage conditions. Each peptide retains its individual amino acid sequence, molecular identity, physicochemical properties, and analytical profile. Independent third-party testing is performed to verify purity and quality specifications for the blend.
What distinguishes the blend formulation from individual peptide preparations?
The blend formulation combines BPC-157 and TB-500 within a single preparation while preserving the individual characteristics of each peptide. This format provides a convenient research tool for investigations involving comparative peptide pharmacology, concurrent evaluation of multiple signaling mechanisms, and studies examining interactions between distinct peptide-associated regulatory pathways.
Researchers requiring separate experimental assessment of each peptide may alternatively utilize the individual preparations.
